Teva Pharmaceuticals
TEVA
460 hedge funds and large institutions have $4.98B invested in Teva Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 92 funds opening new positions, 151 increasing their positions, 114 reducing their positions, and 65 closing their positions.
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
42% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 65
32% more repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 114
5% more funds holding
Funds holding: 437 → 460 (+23)
3.07% less ownership
Funds ownership: 53.83% → 50.76% (-3.1%)
14% less capital invested
Capital invested by funds: $5.76B → $4.98B (-$783M)
38% less call options, than puts
Call options by funds: $273M | Put options by funds: $441M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$142M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$136M |
| 3 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$94.8M |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$83.5M |
| 5 |
Jane Street
New York
|
+$53.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$796M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$195M |
| 3 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$76.9M |
| 4 |
Morgan Stanley
New York
|
-$28M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$26.9M |
TEVA Hedge Fund Activity: Q1 2020 in Review
460 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2020, worth a combined $4.98B — down 14% from $5.76B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new TEVA positions and 65 closed out — a net gain of 27 holders — while 151 added to existing stakes and 114 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $142M. The largest seller was Wellington Management Group, cutting an estimated $796M.
- 460 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2020, up from 437 in Q4 2019.
- Funds reported $4.98B of Teva Pharmaceuticals stock for Q1 2020, down 14% quarter-over-quarter.
- 92 funds opened new Teva Pharmaceuticals positions in Q1 2020 and 65 closed out, a net change of +27 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2020 was Capital International Investors, an estimated $142M added.
- The largest Teva Pharmaceuticals seller in Q1 2020 was Wellington Management Group, an estimated $796M sold.
Based on aggregated 13F filings for Q1 2020.